Lupus & antiphospholipid syndrome
Serum epitope-specific anti-recoverin autoantibodies as biomarkers for lupus retinopathy
Authors' conclusion
Epitope-specific anti-RCV antibodies, especially anti-RCV139-154, may serve as novel biomarkers for early identification of LR in SLE patients.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients with and without lupus retinopathy and healthy controls
- Participants
- 48 / 48 / 44
- Comparison
- SLE with lupus retinopathy (LR) vs SLE without LR vs healthy controls
- LRn = 48
- non-LRn = 48reference
- Healthy controls (HC)n = 44
- Outcome
- Diagnostic performance of serum anti-RCV epitope-specific autoantibodies (RCV55-70, RCV139-154, RCV155-170) for identifying LR
Methodological detailscase-control, epitope prediction (DNAStar, BepiPred-2.0, ABCpred), ELISA
- Case-control
- Epitope prediction (DNAStar, BepiPred-2.0, ABCpred)
- ELISA
Performance
As reported in the abstract
Anti-RCV139-154 for identifying LR from SLE
AUC
0.808
95% CI 0.721–0.895
Sensitivity
54.2%
Specificity
93.8%
Further findings
Epitope-specific anti-RCV antibody levels
- Significantly higher in LR than in non-LR SLE and HC (all p < 0.05)
Correlation of anti-RCV139-154 with SLE disease activity (SLEDAI)
- R (p < 0.001)
- 0.430
- Positive correlation with anti-dsDNA titers and IgG; inverse correlation with C3 and C4 (p < 0.001)
Anti-RCV139-154 in LR subtypes and after treatment
- Preferentially elevated in microvasculopathic LR and declined after treatment
Original publication
Serum epitope-specific anti-recoverin autoantibodies as biomarkers for lupus retinopathy. Arthritis Res Ther. Published 21 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →